A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-07 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Sauropod remains are mostly found in rock formations interpreted as dry or seasonally dry, and the ability to eat large quantities of low-nutrient browse would have been advantageous in such environments.
However, the result of the fight was overturned to a No Contest and Casey was suspended for three months by the Texas Department of Licensing and Regulation after an in-competition sample provided by Casey was found to have an elevated testosterone to epi-testosterone ratio. Several experts questioned the findings and in June 2017 she was exonerated by the UFC after follow up testing showed no evidence of doping. On June 29 the UFC issued a strongly worded statement requesting that "the Texas Department of Licensing and Regulation (TDLR) immediately reverse its ruling and exonerate Cortney of any wrongdoing". In turn, on June 30, the TDLR lifted Casey's three-month suspension and reinstated her victory. Casey faced Felice Herrig on December 2, 2017 at UFC 218. She lost the bout via split decision. Casey fought against Michelle Waterson at UFC on Fox 29 in Glendale, AZ on April 14. Cortney lost the fight via split decision Casey faced Angela Hill on August 25, 2018 at UFC Fight Night 135. She won the fight via split decision. Casey next faced Cynthia Calvillo on February 17, 2019 at UFC on ESPN 1. She lost the fight by unanimous decision. Casey was expected to face Virna Jandiroba on December 7, 2019 at UFC on ESPN 7. However, Casey withdrew from the event for an undisclosed reason and she was replaced by Lívia Renata Souza Casey was scheduled to face Lara Procópio on May 16, 2020 at UFC Fight Night 175 (San Diego).
== Adverse effects and contraindications == Like other antiarrhythmics, ibutilide can lead to abnormal heart rhythms due to its ability to prolong the QT interval, which can lead to the potentially fatal abnormal heart rhythm known as torsades de pointes. Consequently, the drug is contraindicated in patients that are likely to develop abnormal heart rhythms; this includes individuals who have previously experienced polymorphic ventricular tachycardia, have a prolonged QT interval, sick sinus syndrome, or have recently had a myocardial infarction, among other conditions.
===== Herpes simplex ===== Herpes simplex virus (HSV) is the virus that causes genital herpes and oral cold sores, and it can be very dangerous to infants. The CDC advises to continue breastfeeding if there are no open/active lesions on the breast and other lesions covered.
Sources: en.wikipedia.org
Trading with the Enemy Act of 1917 Foreign Assistance Act of 1961 International Emergency Economic Powers Act of 1977 Export Administration Act of 1979 Several laws specifically prohibit trade with certain countries:
== Role in wound healing == A transepithelial potential (TEP) is created by a difference in ion concentrations across a tissue barrier in the body. In humans, a gradient exists between the outermost and innermost layers of skin across the entire body. This gradient can range from 10mV to 60mV, depending on which part of the body is measured. The potential is created by epithelial cells, which pump Cl− ions out of the skin through the apical membrane and transport Na+ ions to the basal side of the epithelium. This is supported by an experiment in which Na+ and Cl− transport was increased by addition of AgNO3, and a corresponding increase in membrane potential was observed. Furosemide, a Cl− efflux inhibitor, also decreased the strength of the field in corneal cells. These potentials are maintained elsewhere on the body, such as in the GI, urinary, and respiratory ducts, as well as the corneal epithelium. When the epithelium is pierced by some kind of wound, the barrier which establishes the electric potential has been removed, and so the TEP cannot be maintained. This creates a lateral EF, running from intact epithelium toward the edges of the wound. These wound EFs last as long as the wound takes to heal, and are involved in guiding various types of cells toward the injury in order to facilitate recovery These lateral fields arise instantaneously upon disruption of the epithelium and gradually increase to their maximum strength. The current strength then declines but is maintained throughout the healing process.
Estrogen promotes cellular development and prevents programmed cell death (apoptosis) via activating specific pathways mediated by estrogen receptors (ER) in various types of cells. Estrogen promotes the development of breast cancers that have estrogen receptor (ER) by stimulating the proliferation and survival of breast cancer cells. Estrogen receptor (ER) is a significant indicator for predicting outcomes and guiding treatment decisions, and it is found in around 75% of breast cancers. Estrogen triggers apoptosis in breast cancer cells as well as other types of cells. Receptor levels rise as individuals age among certain ethnic groups, and typically, white women have greater receptor levels compared to black or Japanese women. It has been hypothesized that the absence of a tumor-suppressor gene may lead to the inability to decrease the activity of estrogen receptors when cells enter the cell cycle or the inability to inhibit the division of cells that have estrogen receptors. This might potentially be a mechanism for the development of breast cancer.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.